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Abstract
Background: Galectin-1 (gal-1) belongs to the family of β-galactoside-binding proteins which primarily recognizes the
Galβ1-4GlcNAc sequences of oligosaccharides associated with several cell surface glycoconjugates. The lectin
recognizes correspondent glycoepitopes on human breast cancer cells. Galectin-1 is expressed both in normal and
malignant tissues. Lymphatic organs naturally possessing high rates of apoptotic cells, express high levels of Galectin-1.
Furthermore galectin-1 can initiate T cell apoptosis. Binding of galectin-1 to trophoblast tumor cells presenting the
oncofetal Thomsen-Friedenreich (TF) carbohydrate antigen inhibits tumor cell proliferation. In this study we examined
the impact galectin-1 has in vitro on cell proliferation, apoptotic potential and metabolic activity of MCF-7 and T-47D
breast cancer cells in dependence to their expression of the Thomsen-Friedenreich (TF) tumor antigen.
Methods: For proliferation and apoptosis assays cells were grown in presence of 10, 30 and 60 μg gal-1/ml medium.
Cell proliferation was determined by a BrdU uptake ELISA.
Detection of apoptotic cells was done by M30 cyto death staining, in situ nick translation and by a nucleosome ELISA
method. Furthermore we studied the impact galectin-1 has on the metabolic activity of MCF-7 and T-47D cells in a
homotypic three-dimensional spheroid cell culture model mimicking a micro tumour environment.
Results: Gal-1 inhibited proliferation of MCF-7 cells (strong expression of the TF epitope) but did not significantly
change proliferation of T-47D cells (weak expression of the TF epitope). The incubation of MCF-7 cells with gal-1 raised
number of apoptotic cells significantly. Treating the spheroids with 30 μg/ml galectin-1 in addition to standard
chemotherapeutic regimes (FEC, TAC) resulted in further suppression of the metabolic activity in MCF-7 cells whereas
T-47D cells were not affected.
Conclusions: Our results demonstrate that galectin-1 can inhibit proliferation und metabolic cell activity and induce
apoptosis in breast tumor cell lines with high expression levels of the Thomsen-Friedenreich (TF) antigen in monolayer
and spheroid cell culture models.
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Background
Galectins belong to the family of lectins and are defined by
specifically binding β-galactosides and by a conserved
sequence motif of amino acids in the carbohydrate
recognition domain (CRD). The first family member to be
described, Galectin-1 (gal-1), is a homodimeric protein with
a single carbohydrate recognition domain of 134 amino
acids [1]. It has been identified to be expressed in lymphoid
organs such as the thymus and lymph nodes, in activated
macrophages and T cells. Furthermore its expression is bal-
ancing immune tolerance [2]. LacNAc is the basic ligand
recognized by gal-1, but it also shows increased avidity to
multiple Galβ1-4GlcNAc sequences presented on branched
N-linked or on repeating LacNAc-residues on N- and
O-linked glycans. Having a single CRD, gal-1 associates
non-covalently under physiological conditions to form a
homodimer and such becomes functionally bivalent. The
bivalent nature entails glycan-mediated cross-linking of cell
surface receptors believed to be essential in inducing
signaling events [3, 4]. Extracellularly, by binding its glycan
ligands, gal-1, exerts various biological effects in different
tissues and on cells, including cell adhesion [5, 6], metasta-
sis [7], cell growth regulation [8, 9], immunosuppression
[10] and apoptosis [3].
Treatment of breast cancer tumor cells with galectin-1
leads to reduced cell binding to laminin and plasma or
placental fibronectin [11]. Increased binding potential
for galectin-1 in breast cancer cells seems to correlate
with a positive lymph node status and with tumor size
and stage, whereas the presence of galectin-1 was identi-
fied as a factor that correlates with a lack of metastatic
lesions in lymph nodes. These results indicate quantita-
tive cell-type-dependent requirements of galectin ligand
presentation during the metastatic cascade [11].
Gal-1 expression is also found in the placenta. The pla-
centa plays a key role in balancing local immuntolerance
which is essential for the mother to accept the embryo dur-
ing pregnancy. This complex process of tolerance allowing
the foetal survival is controlled at the embryo-maternal
interface by factors deriving as well from decidualized
endometrium as from the trophoblast itself. Trophoblasts
display various strategies to evade the destructive attack of
the maternal immune response including expression of
non-classical MHC class I antigens and of complement
regulatory proteins [12, 13]. Chorioncarcinoma cell lines
were evaluated as an experimental model of trophoblast-
derived immunoregulation [14]. We found a strong
expression of the Thomsen-Friedenreich (TF) tumour
antigen in the choriocarcinoma cell line BeWo [15, 16].
The TF antigen (galactose-β1-3 N-acetylgalactosamine;
Galβ1-3GalNAcα1) is a tumor-associated disaccharide
which is occluded by covering structures and inaccessible
to the immune system on the cell surface in most healthy
tissues. It is however exposed and immunoreactive on
most human carcinomas and T-cell lymphomas [17].
Galectin-1 binding to BeWo trophoblast tumor cells
presenting the TF antigen inhibits tumor cell proliferation
[16]. Large amounts of TF tumor antigen have as well
been detected on the outer surface membranes of human
breast carcinomas [17, 18].
The TF antigen and galectins have also already been
implicated in tumour cell adhesion and tissue invasion.
Gal-1 and gal-3 appear to participate both in the
homotypic aggregation of human breast carcinoma cells
MDA-MB-435 and their adhesion to the endothelium.
This adhesion seemed to be mediated involving TF
antigen, as it could be inhibited by a TF-antigen specific
peptide [19].
In a former study we showed that gal-1 shows apoptotic
potential in the human breast cancer line MCF-7 in com-
bination with additional stress stimuli like hyperthermia
or the removal of CO2 and FCS for 20 h [20].
In this article we describe that the binding of gal-1 on
human breast cancer cells can induce inhibition of
proliferation and apoptosis in dependence of their
expression of the TF antigen.
When examining basic biological tumor cell functions
in vitro, conventional monolayer cultures can only act as
a very limited cancer model when it comes to sustaining
the characteristics of the original tumor in vitro. Three
dimensional spheroid cultures of cancer cells may reflect
properties of tumors better than those traditional
monolayer cultures, since they come closer to the in vivo
situation regarding cell differentiation, proliferation, and
cell environment, i.e., cell-cell contacts and different
growth areas [21–23]. In this article we also describe
that in a homotypic spheroid model as well binding of
gal-1 on human breast cancer cells can reduce metabolic
cell activity in dependence of their expression of the TF
antigen.
Methods
Breast cancer cell lines and galectin-1 treatment
For this study we used MCF-7 and T-47D human breast
cancer cell lines obtained from ATCC. Cells were grown in
DMEM (Biochrom, Germany) supplemented with 10 % v/v
foetal calf serum (PAA, Germany) and 2 mM L-glutamin
(Sigma-Aldrich, Munich, Germany), without antibiotics
and antimycotics. For proliferation assays and apoptosis
assays cells were grown in the presence of 10, 30 and 60 μg
galectin-1 (Sigma-Aldrich) per ml serum+ 10 % FCS for
48 h. Untreated cells were used as controls.
Immunocytochemistry
Each cell line was investigated for TF antigen expression
by immunocytochemistry. Cells were grown on three-
well multitest slides (Roth, Karlsruhe, Germany) to
subconfluency, then dried, wrapped and stored at -80 °C.
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After thawing, cells were briefly fixed with formalin
(Merck, Darmstadt, Germany; 5 % in PBS (Biochrom),
5 min). The primary anti-TF antibody (Table 1) was
diluted to 2 μg/ml with PBS and incubated with the
slides overnight at 4 °C. After washing this was followed
by incubation with the biotinylated secondary antibody
from the Vectastain® Elite ABC Mouse IgG Kit (Vector
Laboratories, Peterborough, UK) diluted 1:200 for 30
min. Furthermore we used the Vectastain® Elite ABC Kit
for visualization according to the instructions of the
manufacturer. The slides were finally embedded in
mounting buffer and examined with a Zeiss (Jena,
Germany) Axiophot photomicroscope. Images were
aquired with a digital camera system (Axiocam, Zeiss).
BrdU cell proliferation assay
Cell proliferation was analyzed with a 5-bromo-2′-deoxy-
uridine (BrdU) labelling and detection kit (Roche
Diagnostics GmbH, Mannheim, Germany) according to the
manufacturer’s instructions. In 96-well tissue culture plates,
cells (1 x 105 in 0.1 ml cell culture medium) were grown
for 72 h in the absence (controls) and presence of 10, 30
and 60 μg/ml gal-1. For labelling cells were incubated with
BrdU for 3 h, then fixed and subsequently BrdU incorpor-
ation into the cellular DNA was measured by an ELISA
technique. Cellular proliferation is expressed as percentage
compared to the control. At least 8 replicates were
performed with each cell line.
M30 cytoDEATH apoptosis assay
Caspase activity is one of the earliest apoptosis markers.
The M30 cytodeath assay detects caspase-cleaved Cyto-
keratin 18 in epithelial cells. Culture slides with MCF-7
cells grown in the presence of galectin-1 as described
were treated according to the manufactures protocol
(Alexis Biochemicals). Slides were washed in PBS and
then fixed in ice-cold pure methanol at -20 °C for
30 min. After being washed twice with PBS they were in-
cubated with M30 CytoDEATH Fluorescein antibody
(Table 1) for 30 min at 15–25 °C and then washed again
twice before immunocytochemical evaluation. 10 repli-
cates were performed.
In situ nick-translation (ISNT) apoptosis assay
The in situ nick-translation technique (ISNT) was used to
staining DNA fragmentation and apoptotic bodies on cell
culture slides [20]. Slides were incubated with proteinase K
(20 μg/ml, Qiagen, Germany) for 15 min at room
temperature. After rinsing with distilled water the endogen-
ous peroxidase was quenched with 0.3 % hydrogen perox-
ide for 10 min. Being rinsed once more, the slideswere then
equilibrated in nick buffer (Tris, MgCl2, ß-Mercaptoetha-
nol, 20 mg/ml BSA, distilled water) at room temperature
for 10 min. By incubating the slides with dNTPs and bio-
tinylated 7-dATP (Gibco, USA) diluted in nick buffer for
65 min at 37 °C, the in situ nick-translation was performed.
Terminating buffer (0.3 mol/L sodium chloride and
0.03 mol/L sodium citrate) was used to rinse the chamber
slides at room temperature for 15 min. After having washed
the slides in PBS, they were incubated with extravidin–per-
oxidase (Sigma, Germany) at room temperature for 30 min.
AEC-substrate (Dako, Denmark) was used for colour
development. Afterwards the slides were counterstained
with haemalaun, then washed and mounted. The specificity
of ISNT reactivity was confirmed by human epidermis and
lymph node sections. 10 replicates were performed. Nega-
tive controls were performed by incubation in nick buffer
without dNTPs and biotinylated 7-dATP.
Immunocytochemical evaluation of apoptosis assays
For the evaluation of early apoptosis by M30 cytoDEATH
staining and late apoptosis (in situ nick-translation) the
intensity and distribution of the immunocytochemical
staining reaction was evaluated using a semi-quantitative
method (IRS-score) as previously described [24]. The rate
of apoptosis for M30 cytoDEATH and in situ nick
translation was determined by counting 1500 cells per
chamberslide.
Cell death detection ELISA
Apoptosis was also detected using a quantitative three-
step photometric enzyme immunoassay. The Cell Death
Detection ELISAplus kit (Roche Diagnostics GmbH,
Mannheim, Germany) detects cytoplasmic histone-
associated DNA fragments (mono- and oligonucleo-
somes) in vitro after induced cell death. This assay uses
monoclonal mouse antibodies directed against histones
and DNA in a quantitative sandwich enzyme immuno-
assay. Specific mono- and oligonucleosomes in the cyto-
plasmic fraction of cell lysates can thus be detected. At
first the anti-histone antibody was fixed adsorptively on
the wall of the microplate where non-specific binding
sites were saturated and hence blocked. Second the nu-
cleosomes in the sample were bound to the immobilized
anti-histone antibody via their histone component.
Third, the DNA part of the nucleosome reacted with the
anti-DNA-peroxidase. After washing unbound samples
and reagents, the amount of peroxidase ligated in the
immunocomplex was determined colorimetrically using
ABTS as substrate. Results are presented in Units; Unit
Conversion: 1 mU = 1 x 10-3 OD (1 mU = 0.001 OD). A
total of 8 replicates were performed.
Table 1 Antibodies used for the study
Antigen Antibody Isotype Concentration/Dilution Source
TF NM-TF1 Mouse IgM 2 μg/ml Glycotope
M30 ALX-804-590-T200 Mouse IgG 1:15 Alexis
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Spheroid culture
3D cell culture was performed using a modified liquid
overlay technique as described previously [25]. Briefly,
monolayer cultures of the breast cancer cell lines MCF-7
and T-47D were allowed to reach a minimal confluency of
90 % for spheroid culture. The viability and the cell number
of the cell suspensions used for spheroid culture were
assessed. Only cell suspensions with a viability of at least
90 % were used for spheroid culture. For spheroid formation
5 × 104 vital cells were seeded in 50 μl cell culture medium
per 96-well and cultured for 48 h at 37 °C in a humidified
atmosphere containing 5 % CO2. Using this approach, a
single homotypic spheroid was obtained in each well.
Cancer therapy and cell viability ATP-assay
After 48 h of spheroid formation, chemotherapeutic
agents, namely fluorouracil combined with epirubicin
and cyclophosphamide (FEC) and docetaxel combined
with doxorubicin and cyclophosphamide (TAC) were
administered to the spheroids in clinically relevant com-
binations at the peak plasma concentrations as described
previously [26]. Galectin-1 was applied in a concentra-
tion of 30 μg/ml. Medium (untreated) and solvent con-
trols were included in each experiment. Solvents used to
control the effect of the drugs were 0.2%H2O plus
0.26 % NaCl for FEC therapy, 0.01 % H2O plus 0.21 %
NaCl for TAC treatment and 0.15 % phosphate buffered
saline (PBS) for galectin-1. Each treatment and control
was performed in six replicates. The drugs were allowed
to take effect for a total of 48 h. Chemotherapeutics
were obtained from the pharmacy of the University
Hospital LMU (Munich, Germany). Treatment efficacy
was assessed using an ATP assay (CellTiter-Glo®
Luminescence Cell Viability Assay, G8461, Promega,
Germany) to quantify cell survival in vitro. Mean cell
survival was expressed as percent of residual metabolic
activity relative to the solvent controls.
Statistical analysis
IBM SPSS Statistics for Windows, Version 22.0. ((IBM,
Ehningen,Germany) was used for collection, processing,
and statistical data analysis. The non-parametrical
Wilcoxon test for comparison of the means was used for
statistical analysis. P-values <0.05 were considered statis-
tically significant. For statistical analysis of the results
obtained in the spheroid model, the student’s t-test was
performed for comparison of two samples. For compari-
sons of more than two samples, analysis of variance
(ANOVA) with post-hoc Sidak correction was done.
Results
Expression of TF antigen in breast cancer cell lines
Expression of the Thomsen-Friedenreich (TF) antigen as
a target for gal-1 binding was investigated in human
breast cancer cells of the cell lines MCF-7 and T-47D by
immunocytochemistry. Staining results are presented in
Fig. 1. MCF-7 cells showed strong expression (Fig. 1a)
whereas T-47D showed only weak expression of the TF
epitope (Fig. 1b). All magnification 10x lens.
Cell proliferation assay
As demonstrated in Fig. 2a, gal-1 inhibits proliferation of
MCF-7 cells in a concentration-dependent manner. The
addition of gal-1 at 10 μg/ml, 30 μg/ml, and 60 μg/ml re-
duced cellular 5-bromo-2′-deoxy-uridine (BrdU)-uptake
significantly to 83.8 % (p = 0.008), 67.4 % (p = 0.013), and to
76.2 % (p = 0.006) respectively, compared to non-treated
control cultures (100 %). Gal-1 did not significantly
stimulate proliferation of T-47D cells at concentrations of
10 μg/ml, 30 μg/ml, and 60 μg/ml (p = 0.109) (Fig. 2b).
Evaluation of apoptosis by M30 cytoDEATH
The rate of very early apoptosis detected by M30 stain-
ing in untreated for MCF-7 cells had a mean of 1.7 %
(Fig. 3a, e) evaluated by a semi-quantitative method. In
cells treated with 60 μg/ml gal-1 for 48 h the rate of very
early apoptosis is elevated to up to 6.7 % for MCF-7 cells
(p = 0.005, Fig. 3b, e).
Evaluation of apoptosis by in situ nick-translation (ISNT)
The normal rate of apoptosis in MCF-7 breast cancer
cells had a mean of 1.4 % detected by ISTN (Fig. 3c, e).
The viability of the cells manifested itself in a regular
growth and a good range of mitosis. The exposure with
60 μg/ml gal-1 for 48 h significantly increased apoptosis
in MCF7-cells up to 3.6 % (p = 0.01, Fig. 3d, e).
Evaluation of apoptosis by cell death detection ELISA
DNA fragmentation was quantified by examining the cyto-
plasmic histone-associated DNA fragments (mononucleo-
somes and oligonucleosomes). The incubation of MCF-7
cells with 10, 30 and 60 μg/ml gal-1 enhancing apoptosis to
a maximum of 2.1, 2.7 and 3.2 U, respectively (Fig. 4),
reaching statistically significance for 10 μg/ml (p = 0.018),
30 μg/ml (p = 0.018) and 60 μg/ml (p = 0.028) gal-1
incubation.
Evaluation of metabolic activity in the spheroid model
Homotypic spheroids were prepared from human breast
cancer cells lines and treated with various agents.
Metabolic activity after treatment was measured using
the ATP assay (Fig. 5). Treatment of MCF-7 cells with
30 μg/ml gal-1 decreased the metabolic activity to
79.16 % of solvent control compared to untreated cells
(93.5 %) (p = 0.027). In combination with 1xPPC FEC
30 μg/ml gal-1 further reduced the metabolic activity to
21.9 % of solvent control compared to only 38.4 % FEC
alone (p = 0.016). The same could be shown for
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combination of 30 μg/ml gal-1 with 1xPPC TAC which
led to a reduction to 46.3 % of solvent control compared
to 56.9 % TAC alone (p = 0.031) (Fig. 5a).
In T-47D cells the treatment of homotypic spheroids
with 30 μg/ml gal-1 could not significantly reduce the
metabolic activity to 92.3 % of solvent control compared
to untreated cells (97.2 %). Also the addition of 30 μg/
ml gal-1 to 1xPPC FEC did not significantly alter the
rate of metabolic activity (65.2 % of solvent control
compared to 63.4 % for FEC alone). Neither could the
addition of 30 μg/ml gal-1 to 1xPPC TAC induce a
significant effect (71.9 % of solvent control compared to
74.8 % for TAC alone) (Fig. 5b).
Discussion
Within this study we could show that MCF-7 breast
cancer cells show a strong expression of the TF antigen
or epitope. Ligation of galectin-1 induced inhibition of
proliferation as well as metabolic cell activity and onset
of apoptosis.
The Thomsen-Friedenreich (TF) antigen [27] has been
known as a tumour-associated antigen for a long time
[28]. Masked and covered for example by covalently
linked carbohydrates or physically seperated from the
immune system, TF tumor antigen is present in most
tissues on the surfaces of healthy cells. In its unsubsti-
tuted immunoreactive form it can frequently be found in
cancer and precancerous conditions and in many of
these cases, the increased TF occurrence correlates with
the formation of metastasis and cancer progression [29].
The immunoreactive TF antigen also is expressed by
fetal epithelia [30], can be found on transferrin isolated
from human amniotic fluid [31] and is expressed by the
syncytiotrophoblast and extravillous trophoblast [15].
The absence of TF in an immunoreactive form in non--
carcinomatous postfetal tissues, its presence during an
early fetal phase and its frequent occurance in
carcinomas suggest that TF is a stage-specific oncofetal
carbohydrate antigen.
In epithelial cells, it is mainly associated with mucin-1
(MUC1), a protein belonging to a family of highly
glycosylated proteins lining the apical surface of many
glandular epithelial cells. On tumour cells MUC1 is
posttranslational modified leading to an exposure of the
a b
Fig. 1 Strong expression of TF in MCF-7 cells (a). T47-D cells (b) showed only weak expression of TF. All magnification 10x lens
Fig. 2 Gal-1 inhibits proliferation of MCF-7 cells in a concentration-dependent manner (n = 8). Significant decreases in cell proliferation were induced by
treatment of the cultures with 10 μg/ml (p = 0.008), 30 μg/ml (p = 0.013) μg/ml and 60 μg/ml gal-1 (p = 0.006), respectively (a). Gal-1 did not significantly
stimulate proliferation of T47D cells at concentrations of 10 μg/ml, 30 μg/ml, and 60 μg/ml (p = 0.109) (b)
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TF epitope by incomplete O-glycosylation. In several
tumour entities, like colon [32], lung [33] or gastric cancer
[34], or in cancer of the cervix uteri [35, 36], a correlation
between TF expression and negative prognosis could be
identified. Yet, in other tumour locations, like in breast
cancer, its prognostic impact is indeterminate. On the one
hand high TF expression predicted improved survival [37],
then again another study identified a correlation between
high tumour stage and TF expression [38].
In a former study we could demonstrate that in breast
cancer patients TF is expressed on disseminated tumor
cells in bone marrow (DTC-BM) as well [39]. As there is
little knowledge which of the primary tumours’ factors
correlates with haematogenous dissemination, we have
also investigated the expression of TF antigen of breast
cancer tissues from patients with known BM status at
the time of first diagnosis. Patients with TF-positive
tumours had a favourable prognosis [40]. This contrasts
to studies on gastrointestinal tumours [41]. We hy-
pothesised that at least three factors, dissemination
routes, TF-mediated metastasis formation and the
immunogenicity of TF, together determine the different
prognostic impact of TF expression in different tumour
locations [40].
Results obtained within this study demonstrate that
gal-1 only shows apoptotic potential in TF-expressing





ISNT MCF-7 MCF-7 + 60µg/ml gal-1
Fig. 3 M30 staining in untreated for MCF-7 cells had a mean of 1.7 % (a). In cells treated with 60 μg/ml gal-1 for 48 h the rate of very early apoptosis is
elevated to up to 6.7 % (p = 0.005, b). The normal rate of apoptosis in MCF-7 breast cancer cells had a mean of 1.4 % detected by in situ nick translation
(ISNT, c). The incubation with 60 μg/ml gal-1 for 48 h significantly enhanced apoptosis in MCF7-cells to a maximum of 3.6 % (p = 0.01, d). Results of M30
and ISNT staining are summarized (e) (n = 10)
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breast tumor cell lines together with inhibition of
proliferation. Breast cancer cells which expressed
lower levels of TF showed no onset of apoptosis upon
incubation with gal-1. In a preliminary study of our
group apoptosis could be induced by gal-1 and add-
itional stimuli like hyperthermia or long term removal
of CO2 and FCS [20]. At a concentration of 60 μg/ml
incubation of the cells with gal-1 for 48 h, as done in
the present study, no further stimulus was needed to
significantly increase apoptosis in the 2-D model.
Apart from studying the tumor biological effects gal-1
induces in a traditional monolayer culture model, we
also tested them in a homotypic spheroid model. This
model can come closer to mimicking the assembly of a
tumor since spheroids consist of proliferating and viable
but post-mitotic cell populations as well as cells and
compact structures, often in the spheroid core, which
may contain necrotic or apoptotic cells [23].
In the homotypic spheroid cell culture model
incubation of MCF-7 cells with 30 μg/ml gal-1 for
48 h led to an significantly decreased level of meta-
bolic activity especially when combined with standard
chemotherapeutic regimes (FEC, TAC), whereas T-47D
cells did not respond to gal-1 treatment. Therefore we
hypothesize that gal-1 acts via TF on MCF-7 breast
cancer cells.
Conclusion
Downregulation of tumour cell proliferation and onset
of apoptosis by ligation of the TF epitope in breast
cancer patients could be a first step of new therapeutic
options. For applications in earlier development phases,
homotypic tumor cell line spheroid models are the
preferable choice to determining the impact of treat-
ment on cancer cells separated out of a cell mixture in
a complex tumor. But in vivo tumor tissue is a complex
micro environmental structure, not only consisting of
the organ specific tumor cells, but also of various types
of stromal cells as well as the extra-cellular matrix and
different soluble factors. Therefore predicting biological
response to drug treatment in a 2D- or homotypic 3D
model cannot perfectly reflect in vivo conditions. In a
study in which spheroids were either generated homo-
typic from colon cancer tumor cell lines, or tumor cell
lines co-cultured with stromal cells or spheroids
directly prepared from colon cancer tissues, the three
spheroid models reacted differently to the treatment
with clinically relevant cancer combination therapies
[25]. Therefore to evaluate the putative relevance
galectin-1 and the ligation of the TF epitope could have
in breast cancer treatment regimes, testing in
heterotypic spheroid models could provide further
information.
a b
Fig. 5 Measurement of the metabolic activity of human breast cancer cells in spheroid culture in the ATP assay. Significant decrease of metabolic
activity could be reached by incubation of MCF-7 cells with 30 μg/ml gal-1 compared to untreated cells (p = 0.027). In combination with 1xPPC
FEC (p = 0.016) or 1xPPC TAC (p = 0.031) 30 μg/ml gal-1 further significantly reduced the metabolic activity compared to FEC or TAC alone (a). In
T-47D cells treatment with 30 μg/ml gal-1 could not significantly reduce the metabolic activity compared to untreated cells. Neither did the
addition of 30 μg/ml gal-1 to 1xPPC FEC or 1xPPC TAC significantly alter the rate of metabolic activity compared to FEC or TAC alone (b)
Fig. 4 The incubation of MCF-7 cells with 10, 30 and 60 μg/ml gal-1
enhanced DNA fragmentation and nucleosoma formation, reaching
statistically significance for 10, 30 and 60 μg/ml gal-1 incubation
(p = 0,018; p = 0,018; p = 0.028) (n = 8)
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